mefloquine

Phase 1/2Terminated

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Progressive Multifocal Leukoencephalopathy

Conditions

Progressive Multifocal Leukoencephalopathy

Trial Timeline

Jan 1, 2009 → Nov 1, 2010

NCT ID

NCT00746941

About mefloquine

mefloquine is a phase 1/2 stage product being developed by Biogen for Progressive Multifocal Leukoencephalopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT00746941. Target conditions include Progressive Multifocal Leukoencephalopathy.

What happened to similar drugs?

2 of 20 similar drugs in Progressive Multifocal Leukoencephalopathy were approved

Approved (2) Terminated (4) Active (14)

✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved

✅Imatinib mesylateNovartisApproved

🔄Enzalutamide + PlaceboAstellas PharmaPhase 3

🔄HRS-4357 injection + Enzalutamide；AbirateroneJiangsu Hengrui MedicinePhase 3

🔄Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3

❌FTY720 + PlaceboNovartisPhase 3

🔄BAF312 + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00746941	Phase 1/2	Terminated	Jan 1, 2009	Nov 1, 2010	Progressive Multifocal Leukoencephalopathy

Competing Products

20 competing products in Progressive Multifocal Leukoencephalopathy

See all competitors

Product	Company	Stage	Hype Score
AP01	Avalyn Pharmaceuticals	Phase 2	32
Enzalutamide + Placebo	Astellas Pharma	Phase 3	40
Enzalutamide	Astellas Pharma	Phase 2	35
dirucotide + Placebo	Eli Lilly	Phase 2/3	38
dirucotide	Eli Lilly	Phase 2/3	30
HRS-4357 injection + Enzalutamide；Abiraterone	Jiangsu Hengrui Medicine	Phase 3	47
ABBV-8E12 + Placebo solution for IV infusion on Day 15	AbbVie	Phase 2	27
Placebo + ABBV-8E12	AbbVie	Phase 2	27
ABBV-8E12	AbbVie	Phase 1	29
AZD4635 + Durvalumab + Cabazitaxel	AstraZeneca	Phase 2	35
antisense oligonucleotide + placebo	Novartis	Phase 1	29
Trametinib 2 mg	Novartis	Pre-clinical	26
Everolimus	Novartis	Phase 2	35
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	26
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)	Novartis	Phase 3	47
FTY720 + Placebo	Novartis	Phase 3	32
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	43
Mayzent	Novartis	Pre-clinical	26
BAF312 + Placebo	Novartis	Phase 3	40
Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)	Novartis	Phase 1/2	39